Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.43 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8172308 | 0.82 | MAP2K4 (0.64) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL5373068 | 0.82 | MAPK1 (0.43) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL5379184 | 0.78 | MAP2K4 (0.53) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL5377228 | 0.77 | LRRK2 (0.53) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL5384000 | 0.76 | CSNK1D (0.43) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL5377534 | 0.75 | MKNK1 (0.60) | MAPK1CHEK1 | |
| SCHEMBL5383711 | 0.75 | ALDH1A1 (0.72) | CHEK1 | |
| SCHEMBL5385916 | 0.74 | RPA1 (0.61) | MAP2K4CHEK1 | |
| SCHEMBL5377877 | 0.74 | CSNK1D (0.51) | MAPK1MAP2K4MAPK6CHEK1 | |
| SCHEMBL15239588 | 0.74 | PRKAB2 (0.36) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | Celularity, Inc. | 2007-08-16 | — | — | US | disclosed |
| WO-2005046594-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | PGF, ALPP, CPA1 | MAPK1 3959/4885MAP2K4 4365/4885MAPKAPK2 4359/4885 |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | MAP3K6, MAP3K1, MAPK1 | MAPK1 3/4885MAP2K4 45/4885MAPKAPK2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.